COVID-19 research: an opinion piece
COVID-19 research: an opinion piece
复制标题
DOI：
10.1111/hiv.12913
复制
发表时间：
2020-07-21
期刊：
影响因子：
3
通讯作者：
Rockstroh, J. K.
中科院分区：
文献类型：
--
作者：
Waters, L.;Rockstroh, J. K.
COVID-19在全球范围内的空前规模引发了一场竞赛，以发现降低相关发病率和死亡率的干预措施，并在进行任何程度的严格审查之前迅速发布研究结果。与以前的新型感染爆发一样，抗逆转录病毒药物只是一种药物类别，被认为是一种潜在的预防和治疗策略，缺乏证据和伤害风险。在这里，我们总结了抗逆转录病毒药物治疗COVID-19的证据，作为一种药物，羟氯喹也在HIV中进行了研究，并指出了使用尚未得到有力评估的疗法的一些陷阱。
The unprecedented global scale of COVID-19 globally has triggered a race to discover interventions to reduce associated morbidity and mortality and rapid release of research findings prior to any degree of critical review. As with previous novel infection outbreaks, antiretrovirals are just one drug class that has been held up as a potential strategy for prophylaxis and treatment with scant evidence and risk of harm. Here we summarize the evidence for antiretrovirals to treat COVID-19 and, as a drug that has also been studied in HIV, hydroxychloroquine, and flag some of the pitfalls of using therapies that have not been evaluated robustly.